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Abstract 1 
The role of imaging in myeloma has gained increasing importance over the past few 2 
years. The recently revised definition of myeloma from the International Myeloma 3 
Working Group (IMWG) includes cross sectional imaging as a method to define bone 4 
disease and incorporates the use of cross sectional imaging in the disease definition 5 
for patients with suspected smouldering myeloma. The NICE myeloma guidelines also 6 
recommend cross sectional imaging for patients with suspected myeloma. There is 7 
also increasing use of imaging in disease assessments and the 8 
International Myeloma Working Group has recently incorporated imaging in defining 9 
new response categories of minimal residual disease negativity, with or without 10 
imaging-based evidence of disease. 11 
Plain X-rays have previously been the standard imaging modality included in a 12 
myeloma work up at presentation but evidence is mounting for use of cross-sectional 13 
modalities such as computed tomography (CT), magnetic resonance imaging (MRI) 14 
and 18fluoro-deoxyglucose (18F-FDG) positron emission tomography (PET)/CT. 15 
Funding and therefore availability of newer imaging techniques remains a barrier. 16 
Here, we propose an evidence based approach to the use and technical application 17 
of the latest imaging modalities at diagnosis and in the follow-up of patients with 18 
myeloma and plasmacytoma. 19 
 20 
Methodology 21 
The guideline was compiled according to the BSH process. The Grading of 22 
Recommendations Assessment, Development and Evaluation (GRADE) 23 
nomenclature was used to evaluate levels of evidence and to assess the strength of 24 
 4 
 
recommendations. The GRADE criteria can be found at the website 1 
http://www.gradeworkinggroup.org. 2 
 3 
Literature Review 4 
The literature search entailed a systematic search of MEDLINE and PUBMED for 5 
publications that included an abstract and were published in English between 1980 to 6 
2015 using the following key words: myeloma, plasmacytoma, imaging, CT, PET, MRI. 7 
 8 
Review of the manuscript 9 
Review of the manuscript was performed by the British Society for Haematology (BSH) 10 
Guidelines Committee Haemato-Oncology Task Force, Myeloma UK, the BSH 11 
Guidelines Committee and the Haemato-Oncology sounding board of BSH.  12 
 13 
Introduction 14 
Myeloma is a haematological malignancy that is characterised by the clonal 15 
proliferation of plasma cells and is commonly associated with bone disease. Typically 16 
myeloma presents as multiple focal lesions or a diffuse infiltrate throughout the bone 17 
marrow or both and occasionally with extramedullary disease. Myeloma is preceded 18 
by a premalignant asymptomatic stage known as monoclonal gammopathy of 19 
undetermined significance (MGUS) (Landgren et al, 2009; Weiss et al, 2009). 20 
Smouldering myeloma is an intervening phase between MGUS and myeloma but is 21 
not a single entity; there is a biological spectrum ranging from a stable state resembling 22 
MGUS, which does not progress, to a condition where progression to symptomatic 23 
disease is inevitable. 24 
One of the defining criteria for multiple myeloma is the unequivocal presence of 25 
 5 
 
myeloma bone disease (Dimopoulos et al, 2011; Kyle et al, 2009). The new 1 
International Myeloma Working Group (IMWG) definition of myeloma incorporates 2 
cross sectional imaging and now includes patients with more than one unequivocal 3 
focal bone lesion as a defining myeloma-related event indicating the need for 4 
treatment (Rajkumar et al, 2014). Cross sectional imaging has also been incorporated 5 
into disease assessment in the recently revised IMWG consensus criteria for response 6 
assessment (Kumar et al, 2016) and is likely to be increasingly used for disease 7 
assessment in clinical trials. 8 
This guideline reviews the evidence available for the role of imaging techniques in 9 
multiple myeloma, diagnosis, management of vertebral collapse, evaluation of 10 
treatment response and evaluation at relapse; the role of imaging techniques in the 11 
assessment of plasmacytomas is similarly considered. In addition we provide 12 
guidance where possible on the technical considerations around image acquisition 13 
and reporting.  14 
 15 
Use of imaging for diagnosis 16 
 17 
Skeletal survey 18 
A full skeletal survey has for many years been the standard for assessing the 19 
presence of myeloma bone disease for any patient with suspected myeloma. 20 
Approximately 80% of multiple myeloma patients will have radiological evidence of 21 
skeletal involvement using plain radiography (vertebrae in 66% of patients, ribs in 22 
45%, skull in 40%, shoulder in 40%, pelvis in 30% and long bones in 25%) (Collins, 23 
1998). Sites distal to the elbows and knees are rarely affected (Healy and 24 
Armstrong, 1998). A clear association exists between the extent of disease on the 25 
 6 
 
skeletal survey in terms of the number of lytic lesions at presentation and tumour 1 
load at diagnosis (Durie and Salmon, 1975). Their presence represents a criterion 2 
that defines treatment-requiring myeloma even in the absence of symptoms (IMWG, 3 
2003; Kyle & Rajkumar 2009; Bird et al, 2011). The skeletal survey is widely 4 
available at a relatively low cost, is simple to use and interpret, allows large areas of 5 
the skeleton to be visualised and only exposes patients to relatively low doses of 6 
radiation. Careful documentation of the extent of myeloma bone disease is important 7 
to provide a baseline for future monitoring.  8 
 9 
The major disadvantage of plain X-rays is the significantly lower sensitivity compared 10 
to advanced imaging. Lytic lesions are only demonstrated when at least 30 - 50% of 11 
the trabecular bone has been lost (Snapper and Khan, 1971) and around 20% of 12 
myeloma patients have no abnormal findings by plain X-ray. Plain X-rays cannot 13 
distinguish osteopenia or vertebral collapse caused by myeloma from more common 14 
causes such as early osteoporosis or corticosteroid use. 15 
 16 
A recent systematic review by Regelink et al (2013) confirmed that computed 17 
tomography (CT) and magnetic resonance imaging (MRI) are significantly superior to 18 
plain X-ray for the detection of skeletal lesions, apart from those of the ribs and skull 19 
(Regelink et al, 2013).  20 
 21 
Skeletal surveys can be difficult to tolerate for patients with pain and poor mobility 22 
due to the duration of the assessment and the need to adopt various positions (D’Sa 23 
et al, 2007; Dimopoulos et al, 2009). 24 
 25 
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Method: 1 
If being done as part of the staging procedure of newly diagnosed myeloma, the 2 
skeletal survey should include: 3 
• Postero-anterior (PA) view of the chest 4 
• Antero-posterior (AP) and lateral views of the whole spine, humera and 5 
femora 6 
• Lateral views of the skull 7 
• AP view of the pelvis 8 
• Views of any symptomatic areas.  9 
The dose will vary depending on patient size and equipment used, typically 1.5-10 
2.5mSv for an average 70 kg patient. 11 
Skeletal survey has widespread availability and is well established as an assessment 12 
tool in myeloma, but has poor sensitivity and should be superseded by low- dose CT 13 
scan, PET-CT and WB-MRI. Issues remain relating to lack of capacity and health 14 
economic consequences, but performing both a skeletal survey and cross sectional 15 
imaging will be the least cost effective approach.    16 
 17 
Computed tomography 18 
 19 
CT offers improved sensitivity over plain X-rays in detecting lytic lesions and high 20 
resolution three-dimensional images generated by CT provide a more detailed 21 
evaluation of the bone. Small lytic lesions (<5 mm) that would otherwise be missed 22 
by X-ray imaging are detectable by CT, especially in the vertebrae (Mahnken, et al, 23 
2002; Hur et al, 2007). Therefore, bone changes can be identified earlier and 24 
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potential instabilities and fracture risks estimated with greater reliability [Zamagni et 1 
al, 2012; Horger M et al, 2005), particularly in areas where it is difficult to survey by 2 
plain X-ray, e.g. scapulae and sternum. Given the recently revised classification of 3 
multiple myeloma, CT scanning is a suitable option for patients with suspected 4 
smouldering myeloma, but is not necessary in straightforward MGUS patients, 5 
unless they have skeletal symptoms.   6 
From a practical point of view, CT has the advantage of being quick to perform and 7 
allows patients to lie on their back, without the need to change position. CT is also 8 
helpful for visualising soft tissue involvement, assessing spinal fracture stability, 9 
depicting spinal cord and cauda equina compression (although MRI is superior for 10 
this), guiding needle biopsies and surgical interventions and planning radiotherapy. 11 
Despite a number of advantages, conventional CT uses higher doses of radiation (20 12 
mSv for CT of the neck, chest, abdomen and pelvis) than skeletal survey (1.5-2.5 13 
mSv). This has led to the introduction of whole-body low-dose CT (WBLDCT) which 14 
uses a lower tube voltage (kV) and current (mAS) to reduce the energy delivered to 15 
the patient to an effective dose of approximately 4 – 7 mSv. Dose reduction comes 16 
at a cost of reduced image resolution, but this can be partly offset by new iterative 17 
reconstruction techniques so that WBLDCT can now be performed at a similar dose 18 
to skeletal survey. WBLDCT is recommended as first line novel imaging investigation 19 
in European Myeloma Network guidelines (Terpos et al 2015). Studies have shown 20 
that low dose CT accurately assesses the extent of bone destruction and remains 21 
more sensitive than plain X-rays. In one study, the level of confidence in 48 22 
ambiguous plain X-ray findings was raised when WBLDCT from skull base to knees 23 
was used, increasing the detection of osteolytic lesions in the spine seven-fold 24 
(Kropil et al, 2008), whilst in another it could accurately exclude findings in MGUS 25 
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patients being related to myeloma bone disease (Spira et al, 2012). Studies have 1 
shown WBLDCT outperforms radiographs even in traditionally difficult to assess 2 
areas such as skull and ribs (Princewill et al, 2013). Modern scanners routinely use 3 
1mm resolution which reduces partial volume artefacts which previously hindered 4 
evaluation of ribs. New  post processing software shows promise such as the ability 5 
to review unfolded ribs  (Bier et al, 2016 Homann et al, 2015) and the skull (Ringl et 6 
al 2016) although this is not in routine practise. Dual energy CT is a further 7 
development in which the calcium containing bony structures can be mathematically 8 
subtracted to reveal medullary lesions. Thomas et al (2015) have shown increased 9 
detection of non osteolytic myeloma bone lesions in a series of 32 patients although 10 
found it less sensitive than MRI. Current IMWG guidelines require demonstration of 11 
an osteolytic lesion so this technique is not currently recommended.  12 
 WBLDCT is capable of demonstrating extramedullary disease (Surov et al, 2014) 13 
and correlates with whole-body MRI findings (Wolf et al, 2014). As well as 14 
extramedullary myeloma, WBLDCT demonstrates clinically significant non osseous 15 
incidental findings (NOIF) such as occult carcinoma and infection so careful extra 16 
skeletal review is mandated. Surov et al retrospectively reported an average of 3.2 17 
NOIF per patient which were clinically significant in 36.6% of 93 patients with 18 
myeloma undergoing WBLDCT (Surov et al, 2014) 19 
 20 
Other limitations of CT must also be recognised: For example, it may underestimate 21 
bone marrow disease, particularly if it is diffuse, and cortical bone damage with a 22 
homogeneous appearance may be mistaken for osteoporosis or osteopenia (Horger 23 
et al, 2007; Mahnken et al 2002). Furthermore, traditionally CT has not been used to 24 
measure treatment response or provide prognostic information (Durie, 2006). 25 
 10 
 
However, recently simplified new CT response monitoring criteria have been 1 
proposed. Changes in measurement of 2-4 medullary lesions in the limbs have been 2 
shown to correlate to change in lytic lesions and haematological indices in a series of 3 
78 patients (Schabel et al, 2016). 4 
 5 
Method:  6 
Low-dose CT as an alternative to skeletal survey should incorporate red marrow in 7 
adults since this includes the predominant sites of disease. Body coverage proposed 8 
in the literature is variable but larger series suggest WBLDCT to include roof of skull 9 
to proximal tibial metaphysis (Ippolito et al, 2013). Low-dose CT algorithms 10 
optimised for attenuation correction on positron emission tomography (PET/CT) are 11 
suitable for WBLDCT and should be optimised locally. Low dose CT is given without 12 
IV contrast. As a guide, diagnostic images can be achieved with parameters such as 13 
120 kV, <100 mAs, dose modulation, and iterative reconstruction. 14 
 15 
Recommendations: 16 
• WBLDCT (roof of skull to proximal tibial metaphyses) is an alternative to 17 
skeletal survey where facilities exist. It is a more sensitive technique for initial 18 
screening for lytic lesions in myeloma than skeletal survey but less sensitive 19 
than MRI at detection of medullary infiltration (1C) 20 
• WBLDCT is superior to skeletal survey but less sensitive than MRI for the 21 
detection of medullary infiltration and should be considered in asymptomatic 22 
patients with either 10–60% plasma cells on their trephine biopsy or bone 23 
marrow aspirate or an M-protein of > 30 g/L as the detection of more than one 24 
 11 
 
definite focal lesions is diagnostic of multiple myeloma and an indication for 1 
treatment (1B) 2 
• WBLDCT is recommended, if MRI is not feasible, for assessing disease in 3 
patients with suspected myeloma who remain symptomatic despite having no 4 
evidence of osteolysis on the skeletal survey, or to clarify the significance of 5 
ambiguous plain radiographic findings, such as vertebral compression fracture 6 
or equivocal lytic lesions, especially in parts of the skeleton that are difficult to 7 
visualise on plain X-rays, such as sternum and scapulae, or to delineate the 8 
nature and extent of soft tissue disease. WBLDCT is, however, less sensitive 9 
than whole body MRI for assessing medullary infiltration (1C) 10 
 11 
Magnetic resonance imaging 12 
MRI has emerged as a valuable imaging modality in myeloma because of its ability 13 
to directly visualise the disease within the bone marrow rather than its secondary 14 
effects on cortical bone. It is the most sensitive tool available for detecting marrow 15 
infiltration at an early stage, before bone destruction occurs, as well as offering 16 
improved detection of lesions, particularly in the axial skeleton (Dimopoulos et al, 17 
2015). Several studies have compared MRI (limited or whole body) to skeletal survey 18 
at diagnosis (see Table 1) and have shown that MRI may detect up to 50% more 19 
lesions, although the skeletal survey continues to outperform it at certain sites e.g. 20 
ribs (Walker et al, 2007). Comparison of MRI with CT also indicates that MRI 21 
outperforms CT (Bauer-Melnyk et al 2008, Laroche et al 1996) with a pooled 22 
sensitivity of 91% [95% CI: 88 to 94%] and pooled specificity of 41% [95% CI: 26 to 23 
58%] for MRI in a recent systematic review (Regelink et al, 2013).  24 
 25 
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MRI is useful for confirming a diagnosis of solitary plasmacytoma, by ruling out 1 
additional disease (Dimopoulos et al, 2000; Moulopoulos et al, 1993; Liebross et al, 2 
1998), for detecting lesions in symptomatic patients with myeloma whose skeletal 3 
surveys are normal, for assessing disease burden in patients diagnosed with 4 
nonsecretory or oligosecretory myeloma, and for evaluation of extramedullary 5 
disease (Dimopoulos et al, 2011).  It is the technique of choice for suspected spinal 6 
cord compression (Joffe et al, 1988).  7 
MRI provides greater contrast resolution than CT and has the advantage that it does 8 
not expose patients to radiation. Established MRI protocols include T1-weighted 9 
turbo spin echo, T2-weighted turbo spin echo and short tau inversion recovery 10 
(STIR) sequences. T1- and T2-weighted signal intensity provides the ratio between 11 
cellular and fatty components in the bone marrow, and in myeloma the increased 12 
cellular and decreased fatty components give rise to a hypointense signal on T1-13 
weighted images, and a hyperintense signal T2-weighted images and STIR 14 
sequences. On the whole, published studies have utilised whole body techniques 15 
with STIR and T1 sequences. MRI limited to the spine and pelvis may be performed, 16 
but optimal methods need to be defined for evaluation of the skull and for 17 
determining the preferred extent of coverage of the appendicular skeleton (as 18 
approximately 10% of patients present with extra-axial disease only) (Bauerle et al, 19 
2009).  20 
 21 
MRI can demonstrate patterns of bone marrow involvement which are generally 22 
described as normal, focal, diffuse (homogeneous or heterogeneous), variegated 23 
(also known as salt and pepper), or a combination of these. Normal or variegated 24 
marrow patterns have been associated with lower disease burden, whereas focal or 25 
 13 
 
diffuse marrow patterns have been associated with higher disease burden (Bauer-1 
Melynk et al, 2005). A focal or diffuse pattern of bone marrow involvement is not 2 
unique to myeloma and may be present in other haematological malignancies and in 3 
metastatic disease (Vogler et al, 1988).  4 
 5 
MRI has prognostic value. One study showed that patients with more than seven 6 
focal lesions on initial spinal MRI and cytogenetic abnormalities had a poorer five-7 
year overall survival than patients without these features (37% versus 76%) (Walker 8 
et al, 2007).  The presence of at least one focal lesion or the presence of a diffuse 9 
infiltration pattern on whole body MRI is related to a higher risk of progression of 10 
patients previously labelled as having asymptomatic disease (Hillengass et al, 2010). 11 
The two-year progression rate for such patients with ≤ 1 focal lesion was 20% 12 
compared to 70% for patients with > 1 focal lesion (Hillengass et al, 2010), and 13 
patients with lesions required systemic treatment at an earlier time point than 14 
patients without lesions (16 months versus 46 months) (Hillengass et al, 2014), 15 
similarly to the Greek study group (median 15 months, P=0.001) (Kastritis et al, 16 
2013). The IMWG revised classification is currently restricted to focal involvement 17 
where a lesion of diameter > 5mm is regarded as positive; any equivocal lesions 18 
should be imaged again after three to six months. Symptomatic patients with a 19 
diffuse pattern of marrow involvement at staging have a poorer outcome (Song et al, 20 
2014; Moulopoulos et al, 2005; Lecouvet et al, 1998; Moulopoulos et al, 2012).  21 
Although recognised as a prognostic factor, diffuse marrow involvement was not 22 
included as an indication to start treatment in patients with suspected smouldering 23 
myeloma and this reflects not only the need for greater evidence but also that 24 
assessment of marrow infiltration can be challenging and subjective. False positives 25 
 14 
 
can occur, e.g. following administration of granulocyte-colony stimulating factor, and 1 
both focal or diffuse bone marrow patterns may represent other malignant 2 
infiltrations, or be caused by a previous bone marrow biopsy (Hanrahan et al, 2010).  3 
Image enhancement with contrast agents such as gadolinium-diethylene triamine 4 
pentaacetic acid (DTPA) may not always be possible as these agents should be 5 
avoided in patients with renal dysfunction because of the risk of nephrogenic 6 
systemic fibrosis (Nicholas et al, 2012). The main limitation of MRI is the long 7 
acquisition time (up to one hour) which may be difficult to tolerate for those with 8 
severe back pain, or those who suffer from claustrophobia. It is also contraindicated 9 
in patients with cardiac pacemakers and metallic prostheses.  10 
 11 
At present, there is no evidence to indicate that MRI is necessary for patients with 12 
MGUS, although a recent study suggested it might be useful to help identify MGUS 13 
and the various stages of myeloma (Kloth et al, 2014]. 14 
 15 
Newer MRI protocols enable whole-body T1 ± gadolinium contrast agent 16 
administration, T2 ± fat saturation and diffusion-weighted sequences to be 17 
performed. Quantification of skeletal apparent diffusion co-efficient, vascularity and 18 
marrow fat fraction may be possible with diffusion-weighted, dynamic contrast-19 
enhanced and T1 DIXON sequences (Koutoulidis et al, 2017). These sequences 20 
capture the physiological changes that may occur with plasma cell infiltration in 21 
addition to the morphological changes including a higher signal on high b-value 22 
diffusion weighted sequences, a higher apparent diffusion co-efficient compared to 23 
normal bone marrow on diffusion-weighted sequences; a higher vascularisation 24 
 15 
 
compared to normal bone marrow on contrast enhanced sequences and a lower fat 1 
fraction compared to normal marrow. For example at initial staging diffusion 2 
sequences are highly sensitive to diffuse marrow infiltration in comparison to 3 
standard TSE and STIR sequences. Nevertheless, although these techniques have 4 
the potential to improve the specificity of MRI, good quality whole body MRI evidence 5 
remains limited as to their usefulness at diagnosis; instead they may better serve in 6 
other settings e.g. response monitoring where a change in quantitative parameters 7 
such as apparent diffusion co-efficient may be warranted, until there is further high 8 
quality evidence from multi-centre prospective trials (Messiou et al, 2012; Huang et 9 
al, 2012; Messiou et al, 2015) 10 
 11 
Method: 12 
Whole body MRI (typically from the vertex to knees) is recommended. Increasing 13 
coverage to below knees improves sensitivity but is offset by increased time for the 14 
examination. Whole body MRI should include fast T1- and T2-weighted imaging with 15 
fat suppression (e.g. STIR) in either the axial or coronal plane. With MRI scanners 16 
capable of diffusion-weighted imaging, the acquisition should be performed with at 17 
least two b values (e.g. b 50 and 900 s/mm2). An additional T1-weighted sagittal 18 
spine sequence should be incorporated to facilitate assessment of vertebral collapse 19 
and cord compression. Where whole body MRI cannot be performed, STIR and T1-20 
weighted sagittal spine and axial pelvis sequences should be performed. 21 
Recommendation 22 
• MRI is the gold standard for the detection of bone marrow infiltration by 23 
plasma cells in patients with suspected myeloma (2B).  24 
 16 
 
• MRI has superior detection of lesions compared to skeletal survey and should 1 
be considered in asymptomatic patients with either 10–60% plasma cells on a 2 
trephine biopsy or bone marrow aspirate or an M-protein of > 30 g/L as the 3 
detection of more than one definite focal lesions is diagnostic of multiple 4 
myeloma and an indication for treatment (1B).  5 
• MRI is the recommended technique in patients with suspected myeloma who 6 
remain symptomatic despite having no evidence of osteolysis on the skeletal 7 
survey and to clarify the significance of ambiguous plain radiographic findings, 8 
such as vertebral compression fracture or equivocal lytic lesions, especially in 9 
parts of the skeleton that are difficult to visualise on plain X-rays such as 10 
sternum and scapulae and to delineate the nature and extent of soft tissue 11 
disease (2C).  12 
• Where whole body MRI is not possible, MRI of the spine and pelvis may be 13 
performed but may not detect up to 10% of lesions located in the appendicular 14 
skeleton (2C). Where MRI cannot be performed, low-dose whole body CT is 15 
an alternative but has lower sensitivity and specificity for marrow infiltration. 16 
(2C). 17 
 18 
Positron emission tomography/computed tomography (PET/CT) 19 
PET uses 18Fluorine-fluoro-deoxy-glucose (18F-FDG) as a radiotracer to detect 20 
glucose metabolism throughout the body, making use of the fact that tumour cells 21 
have a higher metabolic rate than normal cells and, therefore, higher 18F-FDG 22 
uptake. Uptake can be estimated by calculating the standardised uptake value 23 
(SUV), which is the uptake of 18F-FDG corrected for administered dose and patient 24 
 17 
 
weight. 1 
 2 
FDG PET imaging has limited spatial resolution but combining it with CT imaging 3 
addresses this issue and enables areas of active disease to be identified with exact 4 
anatomical localisation (Zamagni et al, 2012; Agarwal et al, 2013; Nakamoto et al, 5 
2014). This type of information is valuable in myeloma and FDG PET/CT has a 6 
potential role in initial diagnosis (Walker et al, 2012), particularly in extramedullary 7 
disease and non secretory myeloma (Orchard et al, 2002; Dimopoulos et al 2009; 8 
Durie et al, 2002; Agarwal et al, 2013). 9 
 10 
Several studies have shown that FDG PET/CT identifies more lesions than plain X-11 
rays in 40–60% of cases and can also detect lesions in patients with negative 12 
skeletal surveys (Nanni et al, 2006). FDG PET/CT is useful for investigating 13 
equivocal cases when skeletal survey has not detected clear evidence of lytic bone 14 
damage, but patients remain symptomatic (Dimopoulos et al, 2009). It is also useful 15 
for assessing patients with smouldering myeloma and is a recommended imaging 16 
technique for evaluating such cases (Rajkumar et al, 2014). There is little evidence 17 
for a role for FDG PET/CT in stable MGUS patients who are at low risk of 18 
progression to multiple myeloma. Durie et al performed FDG PET/CT scans in a 19 
series of 66 patients with myelomatous and monoclonal disease.  Fourteen patients 20 
had MGUS.  All had normal PET/CT scans and only one patient progressed to 21 
multiple myeloma after eight months (Durie et al 2002).  22 
 23 
The sensitivity of FDG PET/CT in detecting focal lesions in the spine and pelvis is 24 
broadly similar to MRI, but the latter is thought to be superior in detecting diffuse and 25 
 18 
 
variegated bone marrow infiltration (Breyer et al, 2006; Fonti et al, 2008; Mesguich et 1 
al, 2014). In one study, FDG PET/CT was used to detect bone marrow involvement 2 
at initial diagnosis. Sensitivity for the detection of bone marrow involvement shown 3 
on trephine biopsy was 90% while specificity was 100% but interestingly, a 4 
significant correlation was observed between 18F-FDG SUVmax on PET/CT and bone 5 
marrow cellularity and plasma cell ratios on biopsy samples (Sager et al, 2011). This 6 
led to the suggestion that it may be possible to replace bone marrow biopsy with 7 
FDG PET/CT as a marker of disease extent, but further studies are needed to 8 
confirm this, particularly in patients with nonsecretory myeloma. 9 
 10 
FDG PET/CT can provide prognostic information in newly diagnosed myeloma 11 
patients. The presence of three or more lesions was shown initially to be an 12 
independent predictor of overall survival (OS) (Bartel et al, 2009) and in a follow up 13 
study of 429 newly diagnosed myeloma patients in the same institution PET was the 14 
only independent predictor of OS (Usmani et al, 2013). In a European study, the 15 
presence of three or more focal lesions at baseline, a SUVmax greater than 4.2 and 16 
the presence of extramedullary disease adversely affected both progression-free 17 
survival (PFS) and OS (Zamagni et al, 2011).  18 
 19 
The level of FDG uptake on PET/CT may predict pathological fractures. A SUVmax 20 
greater than 3.2 was shown in one study to differentiate between old and new 21 
vertebral fractures, and SUVmax  greater than 3.5 when combined with MRI showing 22 
vertebral body involvement predicted fracture in 5/7 patients either at the time of 23 
imaging or within 10 weeks of the scan. It should be noted, however, that this 24 
retrospective study was limited by small patient numbers (Mulligan et al, 2011). 25 
 19 
 
Fractures are known to adversely affect survival (Sonmez et al, 2008) so the ability 1 
to predict fracture risk with FDG PET/CT is of potential significance, allowing patients 2 
to be managed appropriately and possibly improve outcome. 3 
 4 
FDG PET/CT must be interpreted with care as it has a high rate of false positives 5 
compared to other imaging techniques. False positives can occur in areas of 6 
inflammation or infection, as a result of post-surgical or vertebroplasty changes or 7 
because of the presence of other malignant conditions. On the other hand, false 8 
negatives may occur with concurrent use of corticosteroids and in diabetic patients 9 
with raised blood glucose. To overcome these potential problems, other radiotracers 10 
such as 11C methionine and 18F-fluorodeoxy-L-thymidine (18F-FLT) have been 11 
investigated (Dankerl et al, 2007) but these are not widely available and more 12 
studies are needed to confirm their clinical value in myeloma. Until then, 18F-FDG 13 
remains the radiotracer of choice. The radiation dose is similar to that of 14 
conventional whole body CT  15 
Whole body imaging from vertex to toes is recommended using methods published 16 
in European guidelines for performing 18F-FDG tumour imaging (Boellaard et al, 17 
2015). No standardised criteria currently exist for the interpretation of myeloma 18 
imaging, but recommendations for PET/CT reporting in myeloma are suggested, 19 
based on published experience in the field (Mesguich et al, 2014). Table 2 shows 20 
recommendations for myeloma imaging and reporting using PET/CT and Table 3 21 
shows criteria for the interpretation of FDG bone and bone marrow uptake in patients 22 
with myeloma.  23 
 20 
 
Further recommendations are anticipated in 2017 from an international working 1 
group, involving experts from clinical trials groups and cancer centres, which critically 2 
aim to provide standardisation of PET/CT methods. 3 
 4 
Recommendations: 5 
• FDG PET/CT has superior detection of lesions compared to skeletal survey 6 
and should be considered in asymptomatic patients with either 10–60% 7 
plasma cells on their trephine biopsy or bone marrow aspirate or an M-protein 8 
of > 30 g/L as the detection of more than one definite focal lesions is 9 
diagnostic of multiple myeloma and an indication for treatment. (1B) 10 
• FDG PET/CT may be considered for patients with newly diagnosed 11 
nonsecretory or oligosecretory myeloma and for evaluation of extramedullary 12 
disease. (2C) Although FDG PET/CT has some prognostic value when used 13 
in the initial diagnosis of myeloma, there is currently insufficient evidence to 14 
justify the routine use of FDG PET/CT in all cases of newly diagnosed 15 
myeloma (2C) 16 
 17 
Use of imaging in the management of vertebral collapse/spinal cord 18 
compression 19 
Vertebral compression fractures are common in myeloma and affect up to 70% of 20 
patients during the course of their disease (Lecouvet et al, 1997). Vertebral collapse 21 
causes severe pain and can lead to significant spinal deformity, loss of total body 22 
height, impaired mobility, respiratory compromise and gastro-intestinal discomfort. Of 23 
greatest concern, however, is the risk of spinal cord compression secondary to 24 
 21 
 
vertebral collapse. Plain X-rays are the initial diagnostic modality to confirm a 1 
suspected vertebral fracture, but urgent additional imaging is essential to accurately 2 
characterise spinal disease. Importantly, cord compression can be due to soft tissue 3 
disease. CT scans can accurately identify unstable vertebrae, at risk of fracture 4 
(Horger et al, 2005; Kropil et al, 2008; 51; Touzeau et al, 2013), identify a soft tissue 5 
component, provide better images of more complex fractures and help determine the 6 
degree of vertebral compression (Alexandru et al, 2012).  7 
MRI is the most sensitive and specific imaging modality to assess spinal lesions 8 
(Carlson et al, 1995; Dimopoulous et al, 2015). It enables the morphological 9 
detection of vertebral compression fractures and provides an accurate assessment 10 
of the level and extent of cord or nerve root compression (Joffe et al, 1988; 11 
Moulopoulos et al, 1999; Dimopoulos et al, 2009). Thus, in the event of suspected 12 
cord compression, whole spine MRI including a STIR sequence is the imaging 13 
modality of choice (Dimopoulos et al, 2009; Brooks et al, 2014). Additional CT 14 
imaging may be required to assess spinal instability more accurately both at 15 
diagnosis and in pre-treated patients (particularly as MRI signal intensity and MRI 16 
changes may normalise with treatment).  The spinal instability neoplastic score 17 
(SINS) classification (Fourney et al, 2011) is useful for evaluating the stability of the 18 
spine at the involved levels. This evidence-based classification helps to determine 19 
stability/instability in a spine affected by tumour by taking into account the location in 20 
the spine, pain, lytic nature, alignment, percentage vertebral body height loss and 21 
the presence of posterior bony elements: a score between 0‒6 denotes stability, a 22 
score of 7‒12 denotes indeterminate (possibly impending) instability and a score of 23 
13‒18 signifies instability.  24 
 22 
 
 1 
 2 
Recommendation: 3 
• Urgent MRI is the diagnostic procedure of choice to assess suspected cord 4 
compression in myeloma patients (2B) 5 
• Urgent CT may be used to establish the presence of suspected cord 6 
compression in cases where MRI is either unavailable, not suitable due to 7 
patient intolerance or contraindicated e.g. intraorbital metallic foreign bodies 8 
or cardiac pacemakers (2C) 9 
• Where there is a suggestion of spinal instability on MRI, spinal surgeons may 10 
recommend a CT scan with sagittal and coronal reconstructions to assess for 11 
vertebral body fracture and any involvement of the pars, facet joints and 12 
pedicles. The SINS classification (Fourney et al, 2011) is useful for evaluating 13 
the stability of the spine at the involved levels (2C) 14 
 15 
Use of imaging in the assessment of treatment response and disease relapse 16 
 17 
Assessment of treatment response, monitoring during follow-up and detection of 18 
disease relapse in myeloma patients is predominantly based on paraprotein and 19 
serum free light chain measurement. Imaging is important for reassessing bone 20 
disease at suspected relapse in patients with new bony symptoms and in assessing 21 
disease in patients with nonsecretory, oligosecretory or extramedullary disease. With 22 
modalities that now enable bone marrow infiltration and disease activity to be 23 
 23 
 
measured, imaging has, in fact, the potential to play a wider role in assessing treatment 1 
response and disease relapse. The IMWG has recently incorporated imaging into 2 
disease response assessment (Kumar et al, 2016) and this will lead to imaging being 3 
increasingly incorporated into disease assessment in future clinical trials although it is 4 
unclear how practical this will be in the UK.   5 
 6 
Skeletal survey and CT scan 7 
 8 
Plain X-ray assessment is of limited use in assessing treatment response and in 9 
monitoring as lytic bone lesions seldom show evidence of healing on plain X-rays 10 
(Wahlin et al, 1982). Its role is more restricted to helping define progressive disease 11 
by providing evidence of new bone lesions but caution is needed, as new vertebral 12 
compression fractures on plain X-rays do not necessarily signify disease progression 13 
and may represent structural weakness (Collins, 2005).  14 
 15 
Similarly, CT is not felt to be particularly useful for assessing treatment response, or 16 
for following up bony lesions but further studies are needed to evaluate its use in this 17 
setting. It may be used to demonstrate resolution of extramedullary disease, following 18 
treatment and may help for response assessment of medullary involvement at some 19 
sites e.g. pelvic bones and appendicular skeleton [Horger et al. Cancer 2007].  20 
 21 
 22 
Recommendations: 23 
• There is insufficient evidence of benefit to recommend routine follow up 24 
skeletal survey in untreated asymptomatic patients in the absence of signs of 25 
 24 
 
disease progression (1B) 1 
 2 
• Any new symptomatic areas of the skeleton should be specifically targeted. 3 
However, if disease progression occurs within three months of the previous 4 
skeletal survey, in the absence of new skeletal symptoms, a new skeletal 5 
survey is unlikely to provide additional information 6 
(1B) 7 
 8 
Magnetic resonance imaging 9 
 10 
In the treatment response setting, there is a wide spectrum of treatment-induced 11 
changes with conventional MRI.  12 
In some cases, complete resolution of initial marrow abnormalities is observed in 13 
patients achieving a complete response, while conversion from diffuse to focal or 14 
variegated pattern of infiltration is seen in those achieving a partial response 15 
(Moulopoulos et al, 1994). A good response to treatment can also be demonstrated 16 
by an increase in focal lesion signal intensity on T2-weighted spin echo images, 17 
probably related to necrosis, and the disappearance of contrast-induced rim-18 
enhancement (Bauer-Melnyk et al, 2005). In the post-autologous transplant setting, 19 
one study showed that MRI had 79% concordance with laboratory tests for detection 20 
of persistent disease and a sensitivity of 64% for detection of remission (Bannas et 21 
al, 2012). Another study demonstrated that MRI findings of both focal and diffuse 22 
patterns correlated with treatment response, with there being an inverse correlation 23 
between the number of focal lesions observed at follow up and overall survival 24 
(Hillengass et al, 2012).  25 
 25 
 
In other cases, MRI fails to show evidence of regression of marrow infiltration; focal 1 
lesions may shrink, remain unchanged in size (Lecouvet et al, 2001) or remain 2 
hyperintense as a result of treatment-induced necrosis and inflammation (Rahmouni 3 
et al, 1993). Furthermore, marrow changes can occur following granulocyte colony-4 
stimulating factor (G-CSF) and erythropoietin treatment that cannot be easily 5 
distinguished from active disease (Hartman et al, 2004). In this setting, PET/CT has 6 
an advantage over MRI (see later). 7 
 8 
Recently, more specialised MRI techniques have been developed. Of these, whole-9 
body diffusion weighted MRI (WB-DWI) shows great potential as a technique for 10 
assessing response to treatment. WB-DWI provides information on the difference 11 
between normal and diseased bone marrow architecture, based on differences in the 12 
motion of water at the cellular level (Messiou et al, 2011).  Significant differences in 13 
measured marrow apparent diffusion coefficient (ADC) are observed between non-14 
myeloma and myeloma patients, and between myeloma patients with active and 15 
non-active disease (Messiou et al, 2011; Hillengass et al, 2011; Messiou et al, 2012), 16 
offering a means to quantify both disease burden and response to treatment. ADC is 17 
typically higher for myeloma than normal bone marrow. An increase in ADC may be 18 
seen initially after treatment, presumably due to plasma cell death increasing 19 
extracellular space, followed by normalisation of values when normal marrow 20 
architecture is restored (Messiou et al, 2015). Whilst showing significant promise, 21 
particularly in quantifying response to treatment, further studies are warranted before 22 
WB-DWI can become fully established as a mainstream imaging tool in the 23 
management of myeloma patients. 24 
 26 
 
 1 
Recommendation: 2 
• Conventional MRI may be performed to assess response to treatment but 3 
whole-body diffusion weighted MRI (WB-DWI) should be considered where 4 
available (2C) 5 
 6 
 7 
Positron emission tomography/computed tomography 8 
 9 
FDG PET/CT, due to its ability to distinguish between active and non-active disease 10 
in myeloma, is a potentially powerful modality to assess response to treatment, 11 
predict outcome and guide treatment decisions.  12 
 13 
Successful treatment is accompanied by a reduction or resolution of 18F-FDG uptake 14 
and allows for earlier evaluation as metabolic changes precede morphological 15 
changes (Caldarella C et al, 2012). Conversely, detection of increasing focal uptake 16 
of 18F-FDG, either in old lytic sites or in new areas is an early indicator of relapse. 17 
The usefulness of FDG PET/CT in the assessment of treatment response was 18 
confirmed in a meta-analysis of 10 studies involving 690 myeloma patients based on 19 
its ability to differentiate between metabolically active and inactive lesions (Caldarella 20 
et al, 2012).  It is particularly useful for the approximately 1% of myeloma cases that 21 
are truly nonsecretory and the up to 5% of cases who have oligosecretory disease 22 
with discrepantly low intact monoclonal product or serum free light chain compared 23 
with tumour load, measured either by bone marrow biopsy or imaging. Nonsecretory 24 
and oligosecretory disease become more common with disease progression, with 25 
 27 
 
loss of secretory capacity of some tumours at relapse (Larson et al, 2012). Current 1 
practice in such cases often relies on serial bone marrow biopsies, which are painful 2 
and distressing for patients. FDG-PET (Durie et al, 2002; Larson et al, 2012) and 3 
diffusion weighted MRI (Messiou and Kaiser, 2015) are particularly attractive options 4 
for monitoring nonsecretory or oligosecretory myeloma, either as a standalone 5 
measure of disease, or in conjunction with less frequent bone marrow biopsies. 6 
Furthermore, whole body imaging is less prone to anatomical sampling error than 7 
bone marrow biopsy.  8 
Response assessment by FDG-PET has prognostic value with negative FDG 9 
PET/CT after treatment correlated well with improved outcome (Zamagni et al, 2007) 10 
including following autologous stem cell transplantation (ASCT) (Bartel et al, 2009; 11 
Zamagni et al, 2011; Lapa et al, 2014a). The presence/absence of minimal residual 12 
disease by flow cytometry following initial treatment is prognostic for both PFS and 13 
OS (Rawstron et al, 2015) and FDG-PET assessment will improve this further 14 
(Zamagni et al, 2015) 15 
 16 
Recommendation: 17 
Whole body MRI/diffusion weighted MRI or FDG – PET/CT (at clinician discretion) is 18 
recommended for serial monitoring of disease burden of patients with nonsecretory 19 
myeloma, oligosecretory myeloma (1B) (which can occur at relapse in patients with 20 
previously secretory disease) and extramedullary disease (1B). 21 
 22 
Use of imaging in the assessment of solitary plasmacytoma 23 
 24 
 28 
 
Solitary plasmacytoma is a single lesion (bone more commonly than soft tissue) that 1 
on biopsy shows infiltration by clonal plasma cells with there being no features of 2 
myeloma i.e. no CRAB (calcium elevated, renal failure, anaemia, bone lesions) 3 
features, absence of abnormal plasma cells in random sampling of bone marrow and 4 
normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary 5 
solitary lesion).  6 
 7 
MRI was previously recommended to assess patients with a solitary bone 8 
plasmacytoma in order to exclude other sites of disease, evidence of which would 9 
alter the diagnosis to that of multiple solitary plasmacytomas or multiple myeloma 10 
(Hughes et al, 2009; D’Sa et al, 2007) and change treatment decisions. Moulopoulos 11 
showed additional foci in a third of patients when MRI of the thoracic and 12 
lumbosacral spine was used, indicating that some patients would be under staged if 13 
an MRI was not performed (Moulopoulos et al, 1993). This was supported by 14 
Liebross et al, who demonstrated that a skeletal survey was too insensitive to 15 
diagnose a solitary plasmacytoma (Liebross et al 1998). However, where available, 16 
whole-body MRI should now be considered to allow more thorough assessment of 17 
disease sites elsewhere. 18 
 19 
Due to its ability to identify active disease in both medullary (Kannivelu et al, 2014) 20 
and extramedullary sites (Kim et al, 2014; Lapa et al, 2014b; Mulligan et al, 2011) 21 
FDG PET/CT is also a useful modality for the assessment of suspected solitary 22 
plasmacytoma (Yi et al,  2013; Lu et al. 2012). In several studies, FDG PET/CT 23 
allowed the detection of additional lesions in 30–50% of cases, which had been 24 
missed by plain X-ray or MRI of the spine (Nanni et al 2008; Salaun et al, 2008; 25 
 29 
 
Schirrmeister et al, 2003). The current definition of solitary plasmacytoma requires 1 
the absence of disease outside the primary lesion by bone marrow examination and 2 
MRI (or CT) of spine and pelvis, There is thus lack of clarity  both in terminology and 3 
management of those cases of solitary plasmacytoma defined according to existing 4 
criteria, but which have evidence of PET positivity. There is a lack of data on 5 
performing imaging routinely during follow up, and decisions should be guided by 6 
presence of new symptoms, or biochemical progression.  7 
 8 
 9 
Recommendations: 10 
 11 
• Either FDG PET/CT or whole body MRI should be performed to  exclude 12 
additional sites of disease,  and help to confirm a diagnosis of solitary 13 
plasmacytoma 14 
(1C) 15 
• Repeat imaging should be performed when there is clinical suspicion of 16 
relapse or biochemical progression (1C) 17 
 18 
Summary 19 
Although it is clear that newer imaging techniques are replacing skeletal surveys for 20 
assessing myeloma-related bone disease in people with newly diagnosed myeloma, 21 
funding and availability for these techniques remains a barrier in most healthcare 22 
systems. The comparative effectiveness of whole-body MRI, diffusion weighted MRI, 23 
FDG PET/CT and whole-body low-dose CT is not clear. Defining patients with 24 
 30 
 
suspected myeloma is extremely difficult, but it is clear that imaging is not necessary 1 
for patients with an obvious diagnosis of MGUS. Future research outcomes of 2 
interest are the cost effectiveness, lesion detection, sensitivity and specificity for 3 
myeloma-related bone disease, patient acceptability, incremental upstaging, 4 
radiation exposure, risk of second primary cancer, value in monitoring and the 5 
impact of additional information for predicting PFS, OS and skeletal-related events. 6 
 7 
  8 
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Table 1. Studies investigating MRI in the diagnostic setting with a skeletal 1 
survey (SS) or computed tomography (CT) as the reference standard 2 
 3 
 
Imaging 
test 
 
Reference 
standard 
 
Patients  
 
Whole 
body 
 
MM 
stage 
 
Reference 
 
MRI 
 
SS 
 
60 
 
Yes 
 
SD I-III 
 
Dinter, et al, 2009 
 
MRI 
 
SS 
 
45 
 
Yes 
 
SD I-III 
 
Ghanem et al, 2006 
 
MRI 
 
SS 
 
611 
 
No 
 
SD II-III 
 
Walker et al, 2007 
 
MRI 
 
SS 
 
77 
 
No 
 
SD I-III 
 
Baur et al, 2002 
 
MRI 
 
SS 
 
18 
 
No 
 
SD I-III 
 
Mahnken et al, 2002 
 
MRI 
 
SS 
 
80 
 
No 
 
SD I-III 
 
Lecouvet et al, 1999 
 
MRI 
 
SS 
 
55 
 
No 
 
SD I 
 
Mariette et al, 1999 
 
MRI 
 
SS 
 
23 
 
No 
 
SD I 
 
Dimopoulos et al, 
1993 
      
 56 
 
MRI CT 41 Yes SD I-III Baur-Melnyk et al, 
2008 
 
MRI 
 
CT 
 
48 
 
No 
 
SD I-III 
 
Laroche et al, 1996 
 1 
 2 
  3 
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Table 2 Recommendations for myeloma imaging and reporting using PET/CT  * 
Whole body imaging should be performed from vertex to toes, if tolerated, using 
European guidelines for tumour imaging with FDG 60 m post-FDG administration 
[Boellaard et al 2015] 
 
The following should be reported : 
1. Number of Focal lesions (FL) with increased FDG uptake ( > 3 FL shown to 
be prognostic at diagnosis and during treatment) and distribution and 
standardised uptake values (SUV)max as appropriate 
Note MM lesions may have focal uptake with no CT abnormality, osteolytic 
change or soft tissue density within marrow spaces  
2. Presence of associated CT findings e.g. osteolytic lesions, osteoblastic 
lesions, acute and chronic fractures, pathological fractures  
3. Presence of extramedullary disease  
to be differentiated from ‘break-out lesions’ where the lesion involves bone 
with cortical disruption and soft tissue extension.  Size of soft tissue 
mass/es may be helpful. 
4. Risk of cord compression or invasion of base of skull  
5. Presence of diffuse bone marrow uptake > liver  
6.  Sites for possible biopsy if appropriate 
7. Other relevant findings such as infection- or disease-related complications 
e.g. avascular necrosis, osteonecrosis 
8. Previous surgical interventions e.g. vertebroplasty, prostheses and 
orthopaedic devices 
*Modified from Mesguich et al European Journal of Radiology 2014; 83: 2203-2223 1 
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 1 
Table 3 Interpretation of FDG bone and bone marrow uptake in patients with 2 
myeloma * (given the limited evidence it is not possible to give a consensus on 3 
the interpretation of extramedullary disease) 4 
Patterns of 
uptake 
Pre treatment Post treatment Other causes of 
‘false positive’  
FDG uptake  
Focal bone 
uptake 
Positive:  
Intensity > uptake in 
normal bone marrow 
and/or normal liver 
with or without lytic 
changes on CT 
(although lytic 
changes needed for 
IMWG definition**)  
 
Negative:  
Uptake that 
corresponds to 
another cause of 
FDG uptake e.g. 
degenerative joint 
disease 
Positive: intensity > 
normal liver 
with stable or new 
lytic lesion or without 
CT abnormality 
[Note for local RT 
treatment increased 
uptake may occur 
due to inflammation if 
scanned within 3 
months of treatment] 
 
Negative: intensity < 
normal liver 
 
Equivocal: FDG 
uptake associated 
 
Trauma 
Osteoporotic 
fracture  
(especially vertebral 
body, ribs, sacrum) 
Stress fracture, 
Bone infarcts  
(especially femoral 
head) 
Degenerative joint 
disease 
Orthopaedic devices 
and surgical 
interventions 
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Equivocal: 
Uptake 
corresponding to rib 
fracture or bone 
lesions with sclerotic 
change on CT 
with previous lytic 
lesion with 
development of 
sclerosis could 
represent treatment 
response  
Diffuse 
bone 
marrow 
uptake 
Positive: 
intensity > normal 
liver 
but reactive changes 
can give similar 
appearances 
Correlation with MRI 
or bone marrow 
biopsy advised as 
appropriate 
 
Negative:  
Intensity ≤ normal 
liver 
Positive:  
Heterogeneous 
uptake > normal liver 
 
Equivocal: 
Homogenous uptake 
should be correlated 
with MRI and 
laboratory data 
Bone marrow colony 
stimulation (though 
not commonly used 
in MM) 
 1 
*Modified from Mesguich et al European Journal of Radiology 2014; 83: 2203-2223 2 
**The revised IMWG definition (Rajkumar et al, 2014) states that increased uptake 3 
on PET-CT alone is not adequate evidence for the diagnosis of a bone lesion due to 4 
 60 
 
multiple myeloma; evidence of underlying osteolytic bone destruction is needed on 1 
the CT portion of the examination. 2 
 3 
Abbreviations: 4 
 5 
 6 
 7 
